
A new drug given to Alzheimer’s patients slowed the disease’s progress by 35 per cent, the latest trial has revealed.
Patients with early stages of Alzheimer’s who were given the drug donanemab showed significantly slowed cognitive and functional decline over an 18-month phase-three trial, according to results published by pharmacutical company Eli Lilly on Thursday.